WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328510

CAS#: 15687-37-3

Description: Naftazone, also known as Etioven, is a vasoprotectant drug used for hemostasis. Naftazone is shown to accelerate human saphenous vein endothelial cell proliferation in vitro at concentrations which did not alter the hemostatic balance.

Price and Availability




Naftazone (Etioven) is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 328510
Name: Naftazone
CAS#: 15687-37-3
Chemical Formula: C11H9N3O2
Exact Mass: 215.0695
Molecular Weight: 215.212
Elemental Analysis: C, 61.39; H, 4.22; N, 19.53; O, 14.87

Synonym: Naftazone; Etioven; C05CX02

IUPAC/Chemical Name: (E)-2-(1-oxonaphthalen-2(1H)-ylidene)hydrazine-1-carboxamide


InChi Code: InChI=1S/C15H19N5/c1-11(15(2,3)4)19-14(18-10-17)20-13-7-5-12(9-16)6-8-13/h5-8,11H,1-4H3,(H2,18,19,20)/t11-/m1/s1

SMILES Code: O=C1/C(C=CC2=C1C=CC=C2)=N/NC(N)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Rascol O, Ferreira J, Nègre-Pages L, Perez-Lloret S, Lacomblez L, Galitzky M, Lemarié JC, Corvol JC, Brotchie JM, Bossi L. A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease. Fundam Clin Pharmacol. 2012 Aug;26(4):557-64. doi: 10.1111/j.1472-8206.2011.00951.x. Epub 2011 May 18. PubMed PMID: 21585523.

2: Jeon DG, Song JG, Kim SK, Kim J. Epidural hematoma after thoracic epidural analgesia in a patient treated with ketorolac, mefenamic acid, and naftazone: a case report. Korean J Anesthesiol. 2014 Mar;66(3):240-3. doi: 10.4097/kjae.2014.66.3.240. Epub 2014 Mar 28. PubMed PMID: 24729848; PubMed Central PMCID: PMC3983422.

3: Walash MI, Belal F, El-Enany N, Eid M, El-Shaheny RN. Stability-indicating HPLC method for determination of naftazone in tablets. Application to degradation kinetics and content uniformity testing. J Chromatogr Sci. 2011 Aug;49(7):495-501. PubMed PMID: 21801479.

4: Durand P, Bloy C, Peltier-Pujol F, Blache D. In-vitro and ex-vivo inhibition of blood platelet aggregation by naftazone. J Pharm Pharmacol. 1996 Jun;48(6):566-72. PubMed PMID: 8832488.

5: Sogni P, Yang S, Pilette C, Moreau R, Gadano A, Avenard G, Bloy C, Lebrec D. Acute and chronic haemodynamic effects of naftazone in portal hypertensive rats. Eur J Pharmacol. 1998 Feb 26;344(1):37-43. PubMed PMID: 9570445.

6: Mattei C, Molgó J, Joseph X, Israel M, Bloy C. Naftazone reduces glutamate cerebro spinal fluid levels in rats and glutamate release from mouse cerebellum synaptosomes. Neurosci Lett. 1999 Aug 27;271(3):183-6. PubMed PMID: 10507699.

7: Herber R, Hercelin B, Van Cantfort J, De Graeve J, Fournel-Gigleux S, Taguchi T, Magdalou J. Reduction and glucuronidation of naftazone by human and rat liver microsomes. Drug Metab Dispos. 1995 Dec;23(12):1305-14. PubMed PMID: 8689937.

8: McGregor L, Chignier E, Bloy C, Rousselle C, Peltier-Pujol F, McGregor JL. Effect of naftazone on in vivo platelet function in the rat. Platelets. 1999;10(1):66-70. PubMed PMID: 16801074.

9: Klein-Soyer C, Bloy C, Archipoff G, Beretz A, Cazenave JP. Naftazone accelerates human saphenous vein endothelial cell proliferation in vitro. Nouv Rev Fr Hematol. 1995;37(3):187-92. PubMed PMID: 7567435.

10: Tadjerouni A, de Muylder JA, Flici O, Vekemans M, Soumenkoff G, Derouaux G, Hubinont PO. [Treatment of non-specific menometrorrhagia with naftazone]. J Gynecol Obstet Biol Reprod (Paris). 1984;13(4):459-62. French. PubMed PMID: 6384352.